Breast cancer cells – antiproliferative effect

The term Breast cancer cells – antiproliferative effect refers to a phenotypic pharmacological endpoint or bioassay result rather than a specific molecular target like a receptor or enzyme. In drug discovery databases such as ChEMBL, this designation is used to categorize experimental data where compounds are tested for their ability to inhibit the growth, division, or viability of breast cancer cell lines, such as MCF-7, MDA-MB-231, or SK-BR-3 (ChEMBL Database, 2024). While achieving an antiproliferative effect is the primary goal of many oncology therapeutics, this outcome can be mediated by a vast array of distinct molecular mechanisms, including the modulation of estrogen receptors, inhibition of human epidermal growth factor receptor 2 (HER2), or disruption of the cell cycle via cyclin-dependent kinases (National Cancer Institute, 2023). Because it represents a broad biological observation rather than a single protein entity, it cannot be assigned a specific molecular classification or a singular mechanism of action. Consequently, it is considered a therapeutic objective or an assay description rather than a defined drug target (PubMed, PMID: 29054312).

Other names

Antiproliferative activity against breast cancer cell linesGrowth inhibition of breast cancer cellsCytotoxicity in breast cancer cellsInhibition of breast cancer cell proliferation

Not applicable as this is a phenotypic endpoint rather than a specific molecular target.